Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice

Objectives This study was conducted to investigate the real‐world effectiveness and tolerability of rituximab‐containing chemoimmunotherapies, which have become the standard of care for chronic lymphocytic leukaemia (CLL), particularly for physically fit patients. Furthermore, current treatment patt...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2018-05, Vol.100 (5), p.455-464
Main Authors: Reiser, Marcel, Dörfel, Steffen, Hensel, Manfred, Hoesl, Mark, Jordan, Wolf‐Oliver, Koenigsmann, Michael, Meyer, Dirk, Reichert, Dietmar, Schwarzer, Andreas, Marquardt, Moritz, Kellershohn, Kerstin, Jentsch‐Ullrich, Kathleen
Format: Article
Language:English
Subjects:
chemoimmunotherapy
Chemotherapy
chronic lymphocytic leukaemia
Chronic lymphocytic leukemia
Clinical medicine
Clinical trials
Comorbidity
Immunotherapy
Leukemia
Monoclonal antibodies
non‐interventional study
Patients
real‐world data
Rituximab
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives This study was conducted to investigate the real‐world effectiveness and tolerability of rituximab‐containing chemoimmunotherapies, which have become the standard of care for chronic lymphocytic leukaemia (CLL), particularly for physically fit patients. Furthermore, current treatment patterns in clinical practice were documented, and an unselected real‐life population was compared with older, comorbid patients. Methods Prospective, multicentre, observational study with rituximab‐containing chemoimmunotherapy in CLL patients. Results Of 681 patients in total, 485 were enroled in cohort 1 (unselected) and 196 in cohort 2 (comorbid “slow‐go” patients). The median patient age was higher than in most randomised controlled trials (cohort 1: 70 years and cohort 2: 75 years). The most common treatment regimen in both first‐line and relapsed patients was rituximab‐bendamustine. Two‐year progression‐free survival rate for first‐line therapy was 84.1% for cohort 1 and 69.8% for cohort 2 (with best overall response rate 81.8% for cohort 1 and 76.6% for cohort 2). General and B‐symptoms declined during treatment and remained at low level or decreased further until study end. The safety profile observed in randomised clinical trials was confirmed. Conclusion Chemoimmunotherapy with rituximab is feasible and safe in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities (ClinicalTrials.gov NCT01178086).
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.13040